ID   OSC-19
AC   CVCL_3086
SY   OSC19; Osc19
DR   CLO; CLO_0009949
DR   ArrayExpress; E-MTAB-3610
DR   BioGRID_ORCS_Cell_line; 978
DR   BioSample; SAMN03471655
DR   Cell_Model_Passport; SIDM00566
DR   Cosmic; 1120701
DR   Cosmic-CLP; 1298362
DR   DepMap; ACH-001625
DR   EGA; EGAS00001000978
DR   GDSC; 1298362
DR   GEO; GSM1670308
DR   JCRB; JCRB0198
DR   JCRB; FDSC0050
DR   LINCS_LDP; LCL-1219
DR   PharmacoDB; OSC19_1205_2019
DR   PRIDE; PXD030304
DR   Wikidata; Q54936575
RX   DOI=10.15114/tr.23.43;
RX   DOI=10.15114/tr.24.57;
RX   DOI=10.15114/tr.35.25;
RX   PubMed=19123955;
RX   PubMed=20215515;
RX   PubMed=21868764;
RX   PubMed=26754630;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=29156801;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=35839778;
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: Japanese.
CC   Doubling time: 33.4 hours (Note=At 12th passage), 25.1 hours (Note=At 28th passage), 16.7 hours (Note=At 55th passage) (DOI=10.15114/tr.23.43).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys164Ter (c.490A>T); ClinVar=VCV000935480; Zygosity=Homozygous (Cosmic-CLP; DepMap).
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.1%; Native American=0.32%; East Asian, North=72.98%; East Asian, South=24.24%; South Asian=0.65%; European, North=1.7%; European, South=0.01% (PubMed=30894373).
CC   Discontinued: JCRB; FDSC0050; true.
CC   Derived from site: Metastatic; Cervical lymph node; UBERON=UBERON_0002429.
ST   Source(s): Cosmic-CLP; DepMap; JCRB; PubMed=21868764
ST   Amelogenin: X,Y
ST   CSF1PO: 12
ST   D13S317: 12
ST   D16S539: 9,12
ST   D18S51: 13
ST   D21S11: 30,31
ST   D3S1358: 14,15
ST   D5S818: 10,13
ST   D7S820: 9,11
ST   D8S1179: 13,15
ST   FGA: 22
ST   Penta D: 9
ST   Penta E: 12,16
ST   TH01: 9
ST   TPOX: 11
ST   vWA: 14 (Cosmic-CLP; JCRB)
ST   vWA: 14,18 (DepMap; PubMed=21868764)
DI   NCIt; C4648; Tongue squamous cell carcinoma
DI   ORDO; Orphanet_457252; Squamous cell carcinoma of the oral tongue
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   61Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 32
//
RX   DOI=10.15114/tr.23.43;
RA   Yokoi T., Yamaguchi A., Odajima T., Furukawa K.;
RT   "Establishment and characterization of a human cell line derived from
RT   a squamous cell carcinoma of the tongue.";
RL   Tumor Res. 23:43-57(1989).
//
RX   DOI=10.15114/tr.24.57;
RA   Yokoi T., Homma H., Odajima T.;
RT   "Establishment and characterization of OSC-19 cell line in serum- and
RT   protein-free culture.";
RL   Tumor Res. 24:57-73(1989).
//
RX   DOI=10.15114/tr.35.25;
RA   Yonekura N., Yokosawa N., Hariya Y., Dehari H., Kohama G.-i.,
RA   Fujii N.;
RT   "Interferon-alpha and interferon-gamma augment apoptosis in oral
RT   carcinoma cells treated with Shiga toxin 2 (Stx2).";
RL   Tumor Res. 35:25-33(2000).
//
RX   PubMed=19123955; DOI=10.1186/1479-5876-7-1;
RA   Kobayashi J.-i., Torigoe T., Hirohashi Y., Idenoue S., Miyazaki A.,
RA   Yamaguchi A., Hiratsuka H., Sato N.;
RT   "Comparative study on the immunogenicity between an HLA-A24-restricted
RT   cytotoxic T-cell epitope derived from survivin and that from its
RT   splice variant survivin-2B in oral cancer patients.";
RL   J. Transl. Med. 7:1.1-1.11(2009).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=21868764; DOI=10.1158/1078-0432.CCR-11-0690;
RA   Zhao M., Sano D., Pickering C.R., Jasser S.A., Henderson Y.C.,
RA   Clayman G.L., Sturgis E.M., Ow T.J., Lotan R., Carey T.E., Sacks P.G.,
RA   Grandis J.R., Sidransky D., Heldin N.-E., Myers J.N.;
RT   "Assembly and initial characterization of a panel of 85 genomically
RT   validated cell lines from diverse head and neck tumor sites.";
RL   Clin. Cancer Res. 17:7248-7264(2011).
//
RX   PubMed=26754630; DOI=10.1186/s13046-016-0284-4;
RA   Hyakusoku H., Sano D., Takahashi H., Hatano T., Isono Y., Shimada S.,
RA   Ito Y., Myers J.N., Oridate N.;
RT   "JunB promotes cell invasion, migration and distant metastasis of head
RT   and neck squamous cell carcinoma.";
RL   J. Exp. Clin. Cancer Res. 35:6.1-6.12(2016).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=29156801; DOI=10.18632/oncotarget.21174;
RA   Kalu N.N., Mazumdar T., Peng S.-H., Shen L., Sambandam V., Rao X.-Y.,
RA   Xi Y.-X., Li L.-R., Qi Y., Gleber-Netto F.O., Patel A., Wang J.,
RA   Frederick M.J., Myers J.N., Pickering C.R., Johnson F.M.;
RT   "Genomic characterization of human papillomavirus-positive and
RT   -negative human squamous cell cancer cell lines.";
RL   Oncotarget 8:86369-86383(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//